Trial · NCT02367014
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) | Assessed at Baseline, Day 5 (end-of-treatment visit) | Change in distance walked as measured by meters on the 6-minute walk test from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Maximum Oxygen Uptake (ml/kg/Min) | Baseline, Day 5 | Change in maximum oxygen uptake as measured by mL/kg/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Ventilatory Efficiency (VE/VCO2 Slope) | Baseline, Day 5 | Change in ventilatory efficiency as measured by the VE/VCO2 slope from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Aerobic Efficiency (ΔO2 Consumption/Δ Work Ratio) | Baseline, Day 5 | Change in aerobic efficiency as measured by ΔO2 consumption/Δ work ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Oxygen Utilization (ΔVO2/ΔlogVE Ratio) | Baseline, Day 5 | Change in oxygen utilization as measured by ΔVO2/ΔlogVE ratio from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Oxygen Uptake Kinetics (Mean Response Time as Measured by Seconds) | Baseline, Day 5 | Change in oxygen uptake kinetics (mean response time) as measured by seconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Pre-exercise Lactate Levels (mg/dL) | Baseline, Day 5 | Change in pre-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Post-exercise Lactate Levels (mg/dL) | Baseline, Day 5 | Change in post-exercise lactate levels as measured by mg/dL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Respiratory Exchange Ratio (VCO2/VO2) | Baseline, Day 5 | Change in peak respiratory exchange ratio as measured by VCO2/VO2 from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Respiratory Rate (Breaths/Min) | Baseline, Day 5 | Change in peak respiratory rate as measured by breaths/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Ventilation (L/Min) | Baseline, Day 5 | Change in peak ventilation as measured by L/min from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Heart Rate (Beats/Min) | Baseline, Day 5 | Change in peak heart rate as measured by beats per minute from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Oxygen Saturation (% O2-saturated Hemoglobin) | Baseline, Day 5 | Change in peak oxygen saturation as measured by percentage of O2-saturated hemoglobin from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Systolic Blood Pressure (mmHg) | Baseline, Day 5 | Change in peak systolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Diastolic Blood Pressure (mmHg) | Baseline, Day 5 | Change in peak diastolic blood pressure as measured by mmHg from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Peak Borg Dyspnea | Baseline, Day 5 | Change in peak Borg dyspnea as measured by 0-10 with 0 meaning no breathlessness and 10 meaning maximal breathlessness from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in VO2 Anaerobic Threshold (mL) | Baseline, Day 5 | Change in VO2 anaerobic threshold as measured by mL from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Watts | Baseline, Day 5 | Change in watts from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in Temperature (°C) | Baseline, Day 5 | Change in temperature as measured by units of Celsius from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
| Secondary | Change in ECG-PR Interval (Msec) | Baseline, Day 5 | Change in PR interval as measured by ECG in milliseconds from baseline (last assessment prior to start of study) to Day 5 (end of treatment visit). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02367014/registered